Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent must be obtained prior to participation in the study~* Must have an additional dose of unexpired, commercial tisagenlecleucel available and prescribed by a physician in the course of medical practice~* Age up to and including 25 years~* Patients must have CD-19+ Leukemia~* Patients who were previously treated with tisagenlecleucel and present with evidence of B-cell recovery as defined by: Peripheral blood (PB) absolute B lymphocyte count ≥ 50/µL, OR PB B lymphocyte ≥ 10% of the total lymphocytes~Exclusion Criteria:~* Prior gene therapy other than tisagenlecleucel~* Prior adoptive T cell therapy other than tisagenlecleucel~* Active CNS involvement by malignancy~* Active or latent hepatitis B or active hepatitis C, or any uncontrolled infection at screening~* HIV positive test within 8 weeks of screening

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Tisagenlecleucel (Type: EXPERIMENTAL): Tisagenlecleucel Cell Dispersion for Infusion given once during the study.~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients \> 50 kg body weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).